AMAG Pharma (AMAG): Makena Auto-Injector And Feraheme Updates Confirm Timely Development Execution - Leerink

October 12, 2016 10:40 AM EDT
Get Alerts AMAG Hot Sheet
Price: $26.00 +2.77%

Rating Summary:
    12 Buy, 7 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade AMAG Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Leerink Partners analyst, Joseph Schwartz, reiterated his Outperform rating on shares of AMAG Pharmaceuticals (NASDAQ: AMAG) after the company announced that the definitive pharmacokinetic and comparative pain studies for the Makena (hydroxyprogesterone caproate) auto-injector program have been initiated and that the Feraheme Phase 3 label expansion trial is enrolling ahead of schedule.

The analyst believes that some investors have doubted the company's ability to execute on Makena studies to support life cycle management (LCM) through auto-injector approval but he maintains his belief that AMAG will execute on these studies and remind investors of the most likely commercial scenarios in 2018+.

No change to the price target of $36.

For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.

Shares of AMAG Pharmaceuticals closed at $23.29 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment